NCT05575518View on ClinicalTrials.gov

A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis

PHASE3RecruitingINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

August 11, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
TuberculosisHuman Immunodeficiency Virus
Interventions
DRUG

Optimised rifamycin

optimised dose rifampicin with or without moxifloxacin

Trial Locations (1)

25401

RECRUITING

Kibong'oto Infectious Diseases Hospital, Moshi

All Listed Sponsors
collaborator

University of St Andrews

OTHER

collaborator

Radboud University Medical Center

OTHER

lead

Stellah Mpagama

OTHER_GOV